Fuxiang Pharmaceutical said on an interactive platform that the recovery in the prices of VC and FEC products as lithium battery electrolyte additives will have a positive impact on the company's performance. The company will actively seize the market opportunities of rising prices of lithium battery electrolyte additive products, and strive to improve overall profitability by relying on cost improvements in the pharmaceutical manufacturing business and strategic advancement of the microbial protein business. Currently, the company has a VC product production capacity of 8,000 tons/year. It plans to increase VC product production capacity to 10,000 tons/year through technical reforms and other measures. The transformation is expected to be completed in the second quarter of 2026.

Fuxiang Pharmaceutical said on an interactive platform that the recovery in the prices of VC and FEC products as lithium battery electrolyte additives will have a positive impact on the company's performance. The company will actively seize the market opportunities of rising prices of lithium battery electrolyte additive products, and strive to improve overall profitability by relying on cost improvements in the pharmaceutical manufacturing business and strategic advancement of the microbial protein business. Currently, the company has a VC product production capacity of 8,000 tons/year. It plans to increase VC product production capacity to 10,000 tons/year through technical reforms and other measures. The transformation is expected to be completed in the second quarter of 2026.